LOTTE BIOLOGICS Brochure

LOTTE BIOLOGICS is a premier global CDMO dedicated to providing top-quality biopharmaceuticals. We have pursued swift global expansion following the acquisition of BMS' Syracuse site, a location with over 62 international regulatory approvals and a 35,000L production capacity. Our capabilities span from cell line development to biologics drug substance manufacturing, with an ADC conjugation facility planned. Future expansion includes three Mega Plants in Korea with a projected capacity exceeding 360,000L, with the first plant expected to be GMP-ready by 2026 and the entire facility fully operational by 2030. Visit https://www.lottebiologics.com/en/